ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities: NCI Offers Funds To Develop, Validate Mouse Models

November 20, 1998

Grassley Seeks Data On Sponsored Travel By NCI Scientists

October 29, 2010

Pastan’s Laboratory Creates “Chimeric” Monoclonal Antibody With Human, Muse

August 12, 1988

FDA Lists Therapies being Tested For AIDS, Opportunistic Infections

January 24, 1992

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

November 28, 2014

AACR Meeting: Celebrex Studies Show Benign Polyp Reduction, Point To Challenges In Biomarker Validation.

April 14, 2006